
A $40B bet on Tylenol; long-term melatonin use; daily vaping doubles among U.S. teens – Morning Medical Update
Key Takeaways
- Kimberly-Clark's acquisition of Kenvue, despite legal challenges, aims to leverage Tylenol's brand strength and a $32 billion portfolio.
 - Preliminary research links long-term melatonin use to increased cardiovascular risks, challenging its perception as a harmless sleep aid.
 
The top news stories in medicine today.
Kimberly-Clark will acquire Kenvue, the Johnson & Johnson spinoff behind Tylenol, Band-Aid and Neutrogena, in a deal worth up to $48.7 billion. The merger creates a consumer health powerhouse but comes as Kenvue faces lawsuits and political scrutiny over unproven claims linking acetaminophen use in pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. have amplified those concerns, though regulators maintain evidence remains inconclusive. Despite investor unease, Kimberly-Clark is betting that Tylenol’s trusted name — and a $32 billion brand portfolio — will endure beyond the controversy. 
Extended use of melatonin supplements may carry cardiovascular risks, according to preliminary findings to be presented at the 
Even as overall youth vaping rates have fallen, adolescents who continue to vape are becoming more heavily addicted, according to new research from the Keck School of Medicine of USC published in 
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.



















